Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The New Microbiologica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 25742149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.

  2014cited by this paper
• Efficacy of Sulbactam and Its Combination with Imipenem, Colistin and Tigecycline in an Experimental Model of Carbapenem-Resistant Acinetobacter baumannii Sepsis

  2014cited by this paper
• Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

  2014cited by this paper
• One-Year Surveillance of ESKAPE Pathogens in an Intensive Care Unit of Monterrey, Mexico

  2013cited by this paper
• In Vitro Activity of Doripenem in Combination with Various Antimicrobials Against Multidrug-Resistant Acinetobacter baumannii: Possible Options for the Treatment of Complicated Infection

  2013cited by this paper
• Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients

  2013cited by this paper
• In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

  2013cited by this paper
• Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.

  2012cited by this paper
• Study of the Correlation of Imipenem Resistance with Efflux Pumps AdeABC, AdeIJK, AdeDE and AbeM in Clinical Isolates of Acinetobacter baumannii

  2012cited by this paper
• Persistence of carbapenem-resistant Acinetobacter baumannii strains in an Italian intensive care unit during a forty-six month study period.

  2012cited by this paper
• In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates

  2012cited by this paper
• Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.

  2012cited by this paper
• Distribution of blaOXA genes among carbapenem-resistant Acinetobacter baumannii nosocomial strains in Poland.

  2012cited by this paper
• Doripenem

  2012cited by this paper
• Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.

  2011cited by this paper
• Economic burden of ventilator associated pneumonia in a developing country

  2011cited by this paper
• Prevalence of Multidrug-Resistant Bacteria at a Tertiary-Care Teaching Hospital in Mexico: Special Focus on Acinetobacter baumannii

  2010cited by this paper
• Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.

  2010cited by this paper
• Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.

  2010cited by this paper
• Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii

  2010cited by this paper
• Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

  2009cited by this paper
• Doripenem: position in clinical practice

  2009cited by this paper
• Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.

  2009cited by this paper
• In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.

  2009cited by this paper
• Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.

  2008cited by this paper
• Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.

  2007cited by this paper
• In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

  2007cited by this paper
• Global Challenge of Multidrug-Resistant Acinetobacter baumannii

  2007cited by this paper
• Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.

  2006cited by this paper
• Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.

  2006cited by this paper
• Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.

  2006cited by this paper
• Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.

  2005cited by this paper
• Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

  2005cited by this paper
• In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain.

  2004cited by this paper
• Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

  2004cited by this paper
• Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii

  2002cited by this paper
• Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.

  2001cited by this paper
• Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit.

  2001cited by this paper
• Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.

  1996cited by this paper

• Risk factors and mortality rates of carbapenem-resistant Gram-negative bacterial infections in intensive care units

  2024cites this paper
• Sulbactam protects neurons against double neurotoxicity of amyloid beta and glutamate load by upregulating glial glutamate transporter 1

  2024cites this paper
• Could the Adoptive Transfer of Memory Lymphocytes be an Alternative Treatment for Acinetobacter baumannii Infections?

  2024cites this paper
• Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant Acinetobacter species using checkerboard assay.

  2023cites this paper
• The efficacy of mesenchymal stem cell treatment and colistin-fosfomycin combination on colistin-resistant Acinetobacter baumannii sepsis model

  2023influential citation
• Carbapenem Combinations for Infections Caused by Carbapenemase-Producing Pseudomonas aeruginosa: Experimental In Vitro and In Vivo Analysis

  2022cites this paper
• Synergistic Activity of Capsaicin and Colistin Against Colistin-Resistant Acinetobacter baumannii: In Vitro/Vivo Efficacy and Mode of Action

  2021cites this paper
• Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

  2021cites this paper
• The investigation of adrenal involvement in carbapenem resistant Acinetobacter baumannii sepsis: experimental mouse model

  2021cites this paper
• Evaluation of Effectiveness of Antibiotic Combination Therapy in Multi Drug Resistant Escherichia Coli in Vitro and in Vivo

  2021cites this paper
• Evaluation of Synergistic Effect of Combined Treatment with Linalool and Colistin on Multidrug-Resistant Acinetobacter baumannii to Expand Candidate for Therapeutic Option

  2020cites this paper
• Environmental Phage-Based Cocktail and Antibiotic Combination Effects on Acinetobacter baumannii Biofilm in a Human Urine Model

  2020cites this paper
• Mesenchymal Stem Cell Therapy for Severe Sepsis and Septic Shock

  2020cites this paper
• Acinetobacter baumannii is an opportunistic pathogen as an MDRO in ICU I

  2019cites this paper
• Comparative Evaluation of In-vitro Synergy Testing Methods in Carbapenem-Resistant Acinetobacter Species

  2019cites this paper
• Acute intraperitoneal infection with a hypervirulent Acinetobacter baumannii isolate in mice

  2019cites this paper
• Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection

  2019cites this paper
• Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.

  2019cites this paper
• In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs.

  2018cites this paper
• Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy

  2017cites this paper
• Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features

  2016cites this paper
• Infection management in patients with sepsis and septic shock in resource-limited settings

  2016cites this paper
• Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

  2016cites this paper
• Colistin and tigecycline resistance in carbapenemase‐producing Gram‐negative bacteria: emerging resistance mechanisms and detection methods

  2016cites this paper
• Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis.

  2016cites this paper
• Combined therapy for multi-drug-resistant Acinetobacter baumannii infection--is there evidence outside the laboratory?

  2015cites this paper
• Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

  2015cites this paper
• In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii

  2015influential citation